Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
4.82B
Market cap4.82B
Price-Earnings ratio
52.81
Price-Earnings ratio52.81
Dividend yield
Dividend yield
Average volume
2.28M
Average volume2.28M
High today
$47.06
High today$47.06
Low today
$45.24
Low today$45.24
Open price
$46.26
Open price$46.26
Volume
506.06K
Volume506.06K
52 Week high
$117.33
52 Week high$117.33
52 Week low
$32.99
52 Week low$32.99

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $45.86, giving the company a market capitalization of 4.82B. It carries a P/E multiple of 52.81.

During the trading session on 2026-01-28, Corcept Therapeutics(CORT) shares reached a daily high of $47.06 and a low of $45.24. At a current price of $45.86, the stock is +1.4% higher than the low and still -2.5% under the high.

Trading volume for Corcept Therapeutics(CORT) stock has reached 506.06K, versus its average volume of 2.28M.

The stock's 52-week range extends from a low of $32.99 to a high of $117.33.

The stock's 52-week range extends from a low of $32.99 to a high of $117.33.

CORT News

TipRanks 22m
Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions

Corcept Therapeutics (CORT) announced an update on their ongoing clinical study. Study Overview This study, officially titled “A Phase 1b/2, Open-Label, Dose-...

Simply Wall St 5d
Corcept Therapeutics Valuation Check After Wild Share Price Swings

If you are wondering whether Corcept Therapeutics at around US$41.30 is priced attractively or not, the key question is how that share price lines up with the c...

Corcept Therapeutics Valuation Check After Wild Share Price Swings
TipRanks 5d
Corcept Therapeutics put volume heavy and directionally bearish

Bearish flow noted in Corcept Therapeutics (CORT) with 4,870 puts trading, or 4x expected. Most active are Feb-26 37.5 puts and Feb-26 40 calls, with total volu...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

More CORT News

TipRanks 5d
Corcept Therapeutics price target raised to $100 from $99 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $100 from $99 and keeps a Buy rating on the shares. The firm noted they reported fina...

Benzinga 6d
Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept Therapeutics Incorporated (NASDAQ:CORT) stock is trading higher on Thursday, with a session volume of 3.06 million. The company’s ROSELLA Phase 3 trial...

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps
Investor's Business Daily 6d
Why Former Highflier Corcept Therapeutics Just Surged Again

Technology Why Former Highflier Corcept Therapeutics Just Surged Again Licensing Corcept Therapeutics (CORT) shares jumped Thursday after the company said its e...

Why Former Highflier Corcept Therapeutics Just Surged Again
TipRanks 6d
Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit

Claim 50% Off TipRanks Premium Corcept Therapeutics ( (CORT) ) has issued an update. On January 22, 2026, Corcept Therapeutics reported that its pivotal Phase...

Simply Wall St 6d
FDA Relacorilant Setback And Legal Probe Might Change The Case For Investing In Corcept

In the past few days, Corcept Therapeutics disclosed that the FDA issued a complete response letter for its cortisol‑targeting drug relacorilant, requiring more...

FDA Relacorilant Setback And Legal Probe Might Change The Case For Investing In Corcept

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.